Scarica l'app Stockscreener
110.46
1.87%
-2.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$112.65
Aprire:
$112.28
Volume 24 ore:
1.53M
Relative Volume:
0.17
Capitalizzazione di mercato:
$191.94B
Reddito:
$44.33B
Utile/perdita netta:
$6.50B
Rapporto P/E:
29.72
EPS:
3.717
Flusso di cassa netto:
$7.40B
1 W Prestazione:
-2.70%
1M Prestazione:
-1.54%
6M Prestazione:
-14.54%
1 anno Prestazione:
-19.52%
Intervallo 1D:
$109.80
$112.45
Intervallo di 1 settimana:
$108.34
$113.95
Portata 52W:
$105.27
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
110.46 | 195.75B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
359.61 | 140.03B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.12 | 117.27B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
70.58 | 106.69B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.65 | 48.94B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
Abbott Laboratories (ABT) Announces $20 Billion Senior Notes Off - GuruFocus
Abbott Formula Linked To 'Horrible' Gut Disease, Ill. Jury Told - Law360
Abbott Laboratories Completes Major Senior Notes Offering - TipRanks
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles (NYSE:ABT) - Seeking Alpha
Abbott Laboratories Pakistan : Board Meeting - marketscreener.com
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Volatility - simplywall.st
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Faces Trial Over Claims Its Infant Formula Caused Bowel Disease in Premature Babies - The Indian Practitioner
Trial over Abbott Laboratories’ formula for premature babies set to begin this week - Times West Virginian
Crossmark Global Holdings Inc. Purchases 12,373 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Labs to face trial on infant formula - The Economic Times
Trial over Abbott Laboratories’ formula for premature babies set to begin in Chicago this week - The Daily Gazette
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Daywatch: Trial over Abbott Laboratories’ formula for premature babies set to begin - Chicago Tribune
Abbott set to face trial over claims premature infant formula caused deadly disease - Reuters
Trial over Abbott Laboratories’ formula for premature babies set to begin in Cook County this week - Chicago Tribune
Dimensional Fund Advisors LP Purchases 169,115 Shares of Abbott Laboratories $ABT - MarketBeat
US002824BU37 Bond Price and Chart — SWB:US002824BU37 - TradingView
Abbott Laboratories EVP Cushman sells $30k in stock - Investing.com Australia
A4EQ5K Bond Price and Chart — GETTEX:A4EQ5K - TradingView
Abbott Laboratories EVP Cushman sells $30k in stock By Investing.com - Investing.com UK
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 613 Shares of Stock - MarketBeat
Abbott Laboratories (NYSE:ABT) EVP Sells $102,288.30 in Stock - MarketBeat
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 263 Shares of Stock - MarketBeat
Insider Sell: Elizabeth Cushman Sells Shares of Abbott Laborator - GuruFocus
Abbott (ABT) SVP Eric Shroff logs share sale and tax disposition - Stock Titan
Abbott Laboratories (ABT) EVP logs 4,997-share tax-withholding disposition on Form 4 - Stock Titan
Abbott (NYSE: ABT) EVP logs share sale and tax disposition - Stock Titan
Abbott (ABT) CEO Robert Ford disposes 30,308 shares for tax withholding - Stock Titan
Abbott Laboratories (ABT) EVP logs tax-withholding disposition of 8,577 shares - Stock Titan
Abbott Laboratories (NYSE: ABT) VP reports sale and tax share disposal - Stock Titan
Abbott Laboratories (ABT) CFO uses 7,441 shares to cover tax withholding - Stock Titan
Abbott (ABT) EVP logs stock sale and tax-withholding share disposal - Stock Titan
How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story - Yahoo Finance
Abbott Labs Finishes Off Suit Over Google, Meta Data Sharing - Bloomberg Law News
Abbott Laboratories Spent $20 Billion to Enter Cancer Diagnostics: Why Analysts See 60% Upside - TIKR.com
Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus - simplywall.st
Better Value & Growth: STE, RMD Lead Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock: Is This Quiet Health Tech Giant Your Next Big US Play? - AD HOC NEWS
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Share Price Weakness? - simplywall.st
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial - Law360
[144] ABBOTT LABORATORIES SEC Filing - Stock Titan
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Futures Contracts for Abbott Laboratories Futures - TradingView
NICE recommends leadless pacemakers to treat slow heart rhythms - BioWorld MedTech
2 Reasons to Like ABT and 1 to Stay Skeptical - StockStory
Abbott wins FDA approval for updated heart failure monitoring device - MedTech Dive
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):